Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
PR Newswire —
Cancer Immunotherapy, LYMPHIR™, launched in the U.S. in December 2025 Completed $36 million in strategic financings, of which $18 million was via private placement and concurrent registered direct offering on December 10, 2025, to strengthen cash position and support continued...